[Skip to Content]
[Skip to Content Landing]
Research Letter
May 2018

Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer

Author Affiliations
  • 1State Key Laboratory of Oncology in South China, Guangzhou
  • 2Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
  • 3Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
  • 4Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Pathology Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
  • 5Quest Genomics, Nanjing, China
JAMA Oncol. 2018;4(5):739-742. doi:10.1001/jamaoncol.2018.0049

Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) demonstrates superior efficacy, compared with chemotherapy, for patients with EGFR-mutant advanced non–small cell lung cancer (NSCLC).1 However, approximately 20% to 30% of patients who receive such treatment exhibit de novo resistance to therapy with EGFR TKIs.2 A better understanding of the underlying mechanisms of this phenomenon is imperative to optimize clinical outcomes.